Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Exact Sciences's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $3,145 Mil. Exact Sciences's Total Assets for the quarter that ended in Dec. 2023 was $6,471 Mil.
Therefore, Exact Sciences's Equity to Asset Ratio for the quarter that ended in Dec. 2023 was 0.49.
The historical rank and industry rank for Exact Sciences's Equity-to-Asset or its related term are showing as below:
EXAS'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.45 Med: 0.58 Max: 0.92
Current: 0.49
During the past 13 years, the highest Equity to Asset Ratio of Exact Sciences was 0.92. The lowest was 0.45. And the median was 0.58.
EXAS's Equity-to-Asset is ranked worse than 61.92% of 239
companies
in the Medical Diagnostics & Research industry
Industry Median: 0.58
vs EXAS: 0.49
Exact Sciences Equity-to-Asset Historical Data
The historical data trend for Exact Sciences's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Exact Sciences's Equity-to-Asset
For the Diagnostics & Research subindustry, Exact Sciences's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Exact Sciences's Equity-to-Asset Distribution in the Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Exact Sciences's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Exact Sciences's Equity-to-Asset falls into.
Exact Sciences Equity-to-Asset Calculation
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Exact Sciences's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Exact Sciences Equity-to-Asset Related Terms
Thank you for viewing the detailed overview of Exact Sciences's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.
Exact Sciences (Exact Sciences) Business Description
Exact Sciences Corporation, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test, a noninvasive stool-based DNA test, is a pre-cancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening, too.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
EXAS has been successfully added to your 